Takeda Pharmaceutical Company Limited

Naoki Iwamura

Shinichi Imamura

Yasuhiro Hirata

Takaharu Hirayama

Masanori Okaniwa

Takuto Kojima

Yasutomi Asano

Terufumi Takagi

Yusuke Sasaki

Tzu-Tshin Wong

Shuji Kitamura

Yasufumi Miyamoto

Yusuke Tominari

Osamu Kurasawa

Yuta Tanaka

Moriteru Asano

Kazuko Yonemori

Ryosuke Arai

Bunnai Saito

Osamu Sano

Koji Ono

Masato Yoshida

Hiroshi Banno

Douglas Robert Cary

Takashi Ichikawa

Arai Ryosuke

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic amide compound

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

The present invention relates to a compound which can be useful for the treatment or prevention of SPT-related diseases including cancer and congenital diseases associated with sphingolipid accumulation (including Niemann-Pick disease).

Heterocyclic compound

The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.

Fused heterocyclic compound

Growing community of inventors

Fujisawa, Japan

Naoki Iwamura